The FDA issued a third complete response letter for ONS-5010/Lytenava, requesting confirmatory efficacy evidence for wet AMD treatment. Lytenava is an ophthalmic bevacizumab formulation, potentially ...

FDA approvals in 2025 introduced novel therapies and devices across ophthalmic subspecialties, emphasizing sustained efficacy ...

Retinal vascular obstruction is an eye disease that causes vision loss by clogging blood vessels that supply nutrition and oxygen to the retina. According to the Health Insurance Review and Assessment ...

The top read ophthalmology articles of 2025 focused on a variety of topics within the field, including links between ...

Lip fillers and blindness a rare but real risk Read ahead to know what experts say you must know before getting lip ...

For women of reproductive age, pregnancy testing is another must before starting GLP-1 therapy. These medications are not recommended during pregnancy, making it essential to confirm pregnancy status ...

Ophthalmologists back AI-powered screening as a game-changer in preventing blindness: Nandita Vijayasimha, Bengaluru Saturday, December 27, 2025, 09:00 Hrs [IST] India’s eye hea ...

Outlook Therapeutics faces a pivotal FDA decision for Lytenava on December 31st, following two prior rejections. Read why ...

The state's current litigation process is clearly designed to protect insurance companies and members of professional medical ...

One of the defining public health stories of 2025 was the return of diseases once thought to be under control. As the world ...

Regeneration work on Wearside saw major milestones in 2025, including the official opening of the Keel Crossing footbridge ...

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that the U.S.